OpportunityAnalyzer: Hodgkin's Lymphoma (HL) - Opportunity Analysis and Forecasts to 2024

From: Fast Market Research, Inc.
Published: Tue Apr 19 2016

Hodgkin's lymphoma (HL), or Hodgkin's disease, is a malignancy which involves the lymph nodes and the lymphatic system. HL is a relatively rare type of cancer, accounting for 12% of all lymphomas and 0.6% of all new cancer cases, but overall prognosis is very good. However, treatment options for those patients who have failed first-line treatment are very few, and a significant unmet medical need remains in those patients. GlobalData estimated the HL market in the 7MM was valued at $316m in 2014. The HL market will increase approximately four-fold over the forecast period, reaching $1.4 billion by 2024 at a CAGR of 16%. This growth will be driven by label extensions for Adcetris (brentuximab vedotin), which is poised to enter earlier lines of HL therapy, as well as the approval and uptake of premium-priced products, such as the immune checkpoint inhibitors, Opdivo (nivolumab) and Keytruda (pembrolizumab). By the end of the forecast period, GlobalData expects Adcetris to retain and extend its lead as the HL market front-runner, with Opdivo and Keytruda making up a significant amount of the market. GlobalData anticipates that pipeline agents will have to show an efficacy advantage over currently used and inexpensive standard of care therapies. The challenge for new entrants in the HL market is to meet the high unmet need of relapsed or refractory (R/R) HL patients, reduce the long-term toxic side effects of current treatments, and improve overall survival.

Full Report Details at
- http://www.fastmr.com/prod/1152417_opportunityanalyzer_hodgkins.aspx?afid=301


Key Questions Answered

* Over the last forty years, only one targeted therapy has been approved for the treatment of HL - Adcetris. The HL space is now filled with excitement because Adcetris label extensions and approval of the first anti-PD-1 therapies are expected to change the treatment landscape. What will be the impact of these newly approved drugs on HL sales?
* With the success of molecular-targeted therapies, including immune checkpoint inhibitors, across the oncology therapy area, what R&D strategies are being leveraged by companies to remain competitive in the HL space?
* The survival of R/R HL patients remains poor, especially for those who fail transplant therapies. Therefore, there are considerably high unmet needs within this indication. What are the main unmet needs remaining in this space? Will the drugs under development fulfil the unmet needs of the HL market?

Key Findings

* One of the main drivers in the expansion of the HL market will be the label extensions of Adcetris in earlier lines of HL therapy, which will include the post-transplantation consolidation setting, as well as newly diagnosed advanced stage patients. The premium-priced anti-PD1-therapies, Opdivo and Keytruda, will also launch and be used in the treatment of the R/R HL population. These drugs are poised to partially meet the remaining unmet medical need of these hard-to-treat patients.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- OpportunityAnalyzer: B-Cell Non-Hodgkin's Lymphoma (NHL) - Opportunity Analysis and Forecasts to 2024
- OpportunityAnalyzer: Acute Myeloid Leukemia (AML) - Opportunity Analysis and Forecasts to 2024
- OpportunityAnalyzer: Glioblastoma - Opportunity Analysis and Forecasts to 2024
- OpportunityAnalyzer: Clostridium difficile Infections (CDI) - Opportunity Analysis and Forecasts to 2024
- OpportunityAnalyzer: Respiratory Syncytial Virus (RSV) - Opportunity Analysis and Forecasts to 2024

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »